Compared to the control group, SGLT2 inhibitors was associated with reduced risk of the secondary outcomes of hospitalization (HR 0.94 (0.90, 0.98), ARR 1.06 (1.36, 1.76)) anemia (HR 0.71 (0.65, 0.76), ARR 2.43 (1.95, 2.90)), and AKI (HR 0.84 (0.79, 0.89), ARR 1.86 (1.29, 2.42)) (Fig. 3, Supplementary Table 4). This evidence concerns the gene SLC5A2 and acute kidney injury.